Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

More News From thebudgetreport.com

The Latest: Mnuchin cautiously optimistic on trade

Apr 21, 2018

WASHINGTON — The Latest on the global finance meetings in Washington (all times local): 1:10 p.m. The International Monetary Fund's policymaking committee says a strong world economy is threatened by increasing tension over trade and a heavy global debt load. Officials say longer-term global prospects are clouded by sluggish productivity growth and aging populations in wealthy countries. Policymakers say in a statement at the end of three days of meetings that countries should take advantage of the broadest-based expansion in a decade and enact reforms that will make their economies more efficient. And cutting government debts is urged. The IMF...

Mnuchin expresses optimism for resolution of trade fights

Apr 21, 2018

WASHINGTON — Treasury Secretary Steven Mnuchin expressed cautious optimism Saturday over efforts to resolve trade tensions that have rattled financial markets and clouded the global economic outlook. Mnuchin held a string of meetings over the past three days with financial officials from China, Japan and Europe over the punitive tariffs the administration has unveiled in an effort to fulfill President Donald Trump's campaign promise to reduce America's huge trade deficits. In a session with reporters, Mnuchin refused to say how close the United States was to resolving the various trade disputes but did indicate progress was being made in the...

AP FACT CHECK: Trump's shifting rationale for firing Comey

Apr 21, 2018

WASHINGTON — President Donald Trump offered a shifting rationale this past week for his firing of FBI Director James Comey and joined other Republicans in exaggerating how much simpler it will become for Americans to file their taxes next time. He also erred, though by just a hair, in claiming a historic achievement in black and Hispanic joblessness. A look behind recent statements on these matters and more: TRUMP: "Slippery James Comey, the worst FBI Director in history, was not fired because of the phony Russia investigation where, by the way, there was NO COLLUSION (except by the Dems)!" —...

Army lowers 2017 recruiting goal; more soldiers staying on

Apr 21, 2018

WASHINGTON — The U.S. Army will not meet its mission to recruit 80,000 active duty soldiers this year and has officially lowered that goal. But Army leaders said the service has been able to encourage more experienced service members to stay on the job to satisfy a growing demand for troops. Army Sgt. Maj. Daniel Dailey said Friday that the updated goal will be 76,500. Six months into the recruiting year, the service has brought in just 28,000 new soldiers. Dailey said the goal is to grow the Army to 483,500, as approved by Congress, and it's up to the...

Slumping tech companies weigh on US stocks

Apr 21, 2018

A steep slide in technology companies weighed on U.S. stocks Friday, pulling the market lower for the second day in a row. Losses among retailers, packaged food and beverage makers and other consumer goods companies also helped weigh down the market. Banks rose as bond yields continued to climb, reflecting increasing investor concerns of higher inflation in the wake of rising oil and other commodity prices. "Higher commodity prices, a little bit more inflation pressure and higher interest rates, that sort of takes some wind out of the sails for equity markets, at least short-term," said Edward Campbell, senior portfolio...

The Budget Report seeks to provide comprehensive coverage and analysis on the current economic, financial issues around the world. First hand finance and economic news all day, every day.

Contact us: sales@thebudgetreport.com